A double-monoclonal immunoenzymometric assay for alpha 1-fetoprotein modified for increased analytical precision.

1987 ◽  
Vol 33 (4) ◽  
pp. 583-586 ◽  
Author(s):  
S Shahangian ◽  
H A Fritsche ◽  
J I Hughes
Keyword(s):  
Reaction Time ◽  
Detection Limit ◽  
Cancer Patients ◽  
Comparison Method ◽  
Tumor Burden ◽  
Reaction Volume ◽  
Modified Method ◽  
One Step ◽  
Final Reaction Volume ◽  
Better Than

Abstract We modified a one-step, two-site, double monoclonal immunoenzymometric assay (Abbott Laboratories) for serum alpha1-fetoprotein (AFP) to increase its sensitivity and improve test precision at the low end. We increased sample size, incubation interval, and reaction time and temperature, and decreased the final reaction volume. Interassay CVs for the modified method ranged from 6.2 to 8.0% for mean concentrations of AFP in serum of 5.2 to 34.2 micrograms/L--substantially better than those for the unmodified monoclonal method--and agreed well with those of the comparison method (modified Abbott polyclonal immunoenzymometric assay). AFP values by the modified monoclonal procedure (y) correlated well with results by the polyclonal method (x): y = 0.983x + 1.84 micrograms/L (r = 0.927, n = 59). The detection limit of the modified monoclonal test was 0.2 microgram/L, as compared with 1.0 and 1.4 micrograms/L, respectively, for the modified polyclonal and the unmodified monoclonal procedures. We recommend using the modified monoclonal method for monitoring cancer patients with low tumor burden.

scholarly journals Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis

2021 ◽  
Vol 9 (3) ◽  
pp. e002096
Author(s):  
Simon Gebremeskel ◽  
Adam Nelson ◽  
Brynn Walker ◽  
Tora Oliphant ◽  
Lynnea Lobert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vesicular Stomatitis Virus ◽  
Cell Activation ◽  
Tumor Burden ◽  
Oncolytic Viruses ◽  
Nkt Cell ◽  
Cell Immunotherapy ◽  
Vesicular Stomatitis ◽  
Better Than

BackgroundOncolytic viruses reduce tumor burden in animal models and have generated promising results in clinical trials. However, it is likely that oncolytic viruses will be more effective when used in combination with other therapies. Current therapeutic approaches, including chemotherapeutics, come with dose-limiting toxicities. Another option is to combine oncolytic viruses with immunotherapeutic approaches.MethodsUsing experimental models of metastatic 4T1 breast cancer and ID8 ovarian peritoneal carcinomatosis, we examined natural killer T (NKT) cell-based immunotherapy in combination with recombinant oncolytic vesicular stomatitis virus (VSV) or reovirus. 4T1 mammary carcinoma cells or ID8 ovarian cancer cells were injected into syngeneic mice. Tumor-bearing mice were treated with VSV or reovirus followed by activation of NKT cells via the intravenous administration of autologous dendritic cells loaded with the glycolipid antigen α-galactosylceramide. The effects of VSV and reovirus on immunogenic cell death (ICD), cell viability and immunogenicity were tested in vitro.ResultsVSV or reovirus treatments followed by NKT cell activation mediated greater survival in the ID8 model than individual therapies. The regimen was less effective when the treatment order was reversed, delivering virus treatments after NKT cell activation. In the 4T1 model, VSV combined with NKT cell activation increased overall survival and decreased metastatic burden better than individual treatments. In contrast, reovirus was not effective on its own or in combination with NKT cell activation. In vitro, VSV killed a panel of tumor lines better than reovirus. VSV infection also elicited greater increases in mRNA transcripts for proinflammatory cytokines, chemokines, and antigen presentation machinery compared with reovirus. Oncolytic VSV also induced the key hallmarks of ICD (calreticulin mobilization, plus release of ATP and HMGB1), while reovirus only mobilized calreticulin.ConclusionTaken together, these results demonstrate that oncolytic VSV and NKT cell immunotherapy can be effectively combined to decrease tumor burden in models of metastatic breast and ovarian cancers. Oncolytic VSV and reovirus induced differential responses in our models which may relate to differences in virus activity or tumor susceptibility.

scholarly journals Municipal Leachate Treatment by Fenton Process: Effect of Some Variable and Kinetics

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Mohammad Ahmadian ◽  
Sohyla Reshadat ◽  
Nader Yousefi ◽  
Seyed Hamed Mirhossieni ◽  
Mohammad Reza Zare ◽  
...  
Keyword(s):  
Reaction Time ◽  
Color Removal ◽  
Molar Ratio ◽  
Order Kinetic ◽  
Fenton Process ◽  
Solution Ph ◽  
Leachate Treatment ◽  
First Order ◽  
Order Kinetic Model ◽  
Better Than

Due to complex composition of leachate, the comprehensive leachate treatment methods have been not demonstrated. Moreover, the improper management of leachate can lead to many environmental problems. The aim of this study was application of Fenton process for decreasing the major pollutants of landfill leachate on Kermanshah city. The leachate was collected from Kermanshah landfill site and treated by Fenton process. The effect of various parameters including solution pH, Fe2+and H2O2dosage, Fe2+/H2O2molar ratio, and reaction time was investigated. The result showed that with increasing Fe2+and H2O2dosage, Fe2+/H2O2molar ratio, and reaction time, the COD, TOC, TSS, and color removal increased. The maximum COD, TOC, TSS, and color removal were obtained at low pH (pH: 3). The kinetic data were analyzed in term of zero-order, first-order, and second-order expressions. First-order kinetic model described the removal of COD, TOC, TSS, and color from leachate better than two other kinetic models. In spite of extremely difficulty of leachate treatment, the previous results seem rather encouraging on the application of Fenton’s oxidation.

Arterial Thrombosis in Cancer Patients: An Update

2021 ◽  
Author(s):  
Massimo Franchini ◽  
Antonella Tufano ◽  
Aniello Casoria ◽  
Antonio Coppola
Keyword(s):  
Cancer Patients ◽  
Arterial Thrombosis ◽  
Cardiovascular Events ◽  
Tumor Burden ◽  
Vascular Events ◽  
Time Period ◽  
Treatment Considerations ◽  
Arterial Thromboembolic Events ◽  
The Individual ◽  
Patients Experience

AbstractCancer is associated with an increased incidence of both venous thromboembolism (VTE) and arterial thrombosis (cardiovascular events and ischemic stroke). Cancer-associated arterial thrombotic events are less well studied than VTE, but increasingly recognized, particularly in specific malignancies and in association with specific anticancer therapies. The pathogenesis of arterial thrombotic events in cancer is complex and involves generation of tumor-associated procoagulant factors and a variety of alterations in platelet function as well as in the coagulation and fibrinolytic systems, and endothelial injury and dysfunction, that combine to produce hypercoagulability. The multifactorial interaction between this prothrombotic state, the individual cardiovascular risk, advanced age and presence of comorbidities, and the specific neoplasm characteristics and therapy, may induce the vascular events. Recent studies based on population databases and prospective or retrospective analyses with prolonged follow-up highlight that cancer patients experience an increased (approximately 1.5–2-fold) risk of both cerebrovascular and cardiovascular events compared with noncancer individuals, which peaks in the time period of the diagnosis of cancer but may persist for years. Beyond the type of cancer, the risk reflects the tumor burden, being higher in advanced stages and metastatic cancers. The occurrence of arterial thromboembolic events is also associated with increased overall mortality. We here present an update of the pathophysiology, risk factors, clinical evidence, and treatment considerations on cancer-associated arterial thrombosis, in the light of the need for specific multidisciplinary prevention and surveillance strategies in this setting, in the frame of cardio-oncology approaches.

Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden

2017 ◽  
Vol 26 (4) ◽  
pp. 395-401 ◽  
Author(s):  
Jagdeep Singh Bhangu ◽  
Hossein Taghizadeh ◽  
Tamara Braunschmid ◽  
Thomas Bachleitner-Hofmann ◽  
Christine Mannhalter
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Tumor Burden ◽  
Cell Free Dna ◽  
Free Dna ◽  
Potential Biomarker ◽  
Colorectal Cancer Patients ◽  
Circulating Cell Free Dna

Dosage du Sr-90 dans l'eau des lacs et des rivières du Québec par précipitation avec l'oxine et comptage β

1988 ◽  
Vol 66 (1) ◽  
pp. 174-177 ◽  
Author(s):  
E. Haddad ◽  
L. Zikovsky
Keyword(s):  
Detection Limit ◽  
Surface Waters ◽  
New Method ◽  
The Mean ◽  
Better Than

A new method for the determination of Sr-90 dissolved in surface waters has been developed. It is based on the precipitation of Sr with 8-hydroxyquinoline at pH 11.3 and counting of β particles with energy above 150 keV. The detection limit obtained is 0.5 mBq/L and the mean yield is 28%. The decontamination factors from other β emitters achieved are better than 10 000. This method has been used to measure the Sr-90 in 5 lakes and 5 rivers in Québec and activities ranging from 3 to 15 mBq/L were obtained. This new method is as efficient and reliable as conventional techniques while being less tedious.

Sign in / Sign up

Export Citation Format

Share Document